Navigation Links
BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
Date:6/1/2008

CHICAGO, June 1 /PRNewswire/ -- BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, today announced positive results from its Phase II clinical trial of OncoVEX GM-CSF, an oncolytic for the treatment of advanced metastatic melanoma, at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL.

Clinical Trial Details

Phase II Trial Design: The Phase II trial was conducted at seven U.S. clinical centers, including the Mary Crowley Cancer Research Center, Dallas, TX; Columbia University, New York, NY; The Hubert H. Humphrey Cancer Center, Minneapolis, MN; and the University of California San Diego, San Diego, CA. Fifty patients with inoperable Stage IIIc/IV melanoma were enrolled. Patients were given OncoVEX GM-CSF injections every two weeks for up to a year. The trial was designed to measure overall objective response, which is defined as a complete response, where disease is completely eliminated, or partial response, where there is a >30% reduction in disease burden. The target efficacy endpoint detailed in the Phase II protocol and agreed with the FDA was to achieve two objective responses or stable disease >2 months.

Phase II results: Among 43 patients currently evaluable of the 50 patients enrolled, tumors injected with OncoVEX GM-CSF routinely responded, often with local complete responses or palliative benefit. With regard to systemic overall responses required for treatment success (including tumor responses at sites distant from injected tumors), six patients showed complete clinical responses; five of which are ongoing at between four and 27 months post first injection. The sixth complete response patient presented with a new lesion 15 months after initiating therapy. A further six patients achieved a partial response, five of which are ongoing 7-13 months post first injection and two of which have no disease after surgical r
'/>"/>

SOURCE BioVex Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
2. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
3. Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO
4. Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives
5. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
6. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
7. DATATRAK International Reports First Quarter Results for 2008
8. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
9. Neurocrine Biosciences Reports First Quarter 2008 Results
10. Phosphagenics Reports Positive Pre-clinical Results for Targeted Delivery of Lidocaine
11. Cardica Reports Positive Top-Line Results and Submits 510(k) for PAS-Port(R) Proximal Anastomosis System in Cardiac Bypass Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014 Leading ... is returning for the seventh year to São Paulo, ... 7 th August 2014. The event will co-locate with ... most comprehensive meeting point for the pharmaceutical industry. ... top 25 countries for pharmaceutical sales are now exploring the ...
(Date:7/25/2014)... -- Dr. Michael Gabriel of a prominent ... recent study, which shows how grief in pregnancy may cause ... According to US News , "Unborn ... than others to grow up overweight or obese, even if ... two specific types of stress that caused obesity: "Children whose ...
(Date:7/24/2014)... , July 24, 2014  PTC Therapeutics, Inc. (NASDAQ: ... will host a webcast conference call to report its ... on the company,s business and outlook on Thursday, August ... of the market. The call can ... 935-8152 (international) five minutes prior to the start of ...
Breaking Medicine Technology:CPhI South America 2014 Launches with Generics Showing Huge Growth 2CPhI South America 2014 Launches with Generics Showing Huge Growth 3CPhI South America 2014 Launches with Generics Showing Huge Growth 4Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2
... CORPAK MedSystems, Inc., a leading developer, manufacturer, ... and bedside-technology markets, today announced the appointment of Jeffrey ... Mr. Blair brings 40 years of healthcare ... the chairman and chief executive officer of North American ...
... 2011 PrimeraDx today announced the launch of the ... market used for simultaneous detection and quantification of disparate ... “We are excited to have launched the ... President and CEO Matthew McManus, MD, PhD.   “No ...
Cached Medicine Technology:CORPAK MedSystems Names Jeffrey Blair Chief Executive Officer 2CORPAK MedSystems Names Jeffrey Blair Chief Executive Officer 3PrimeraDx Launches the Only System Capable of Simultaneous Quantification of mRNA, microRNA and DNA 2
(Date:7/27/2014)... 2014 Bags underneath the eyes is one ... and there are a range of new products now available ... a baggy eyes serum review that is now posted for ... explores the issues with baggy eyes and how the natural ... users. The guide also provides a detailed overview of the ...
(Date:7/27/2014)... hepatitis E virus (HEV) transmission by blood components indicates ... HEV in their plasma. The findings, published in ... components (eg, red cells, platelets, and fresh frozen plasma) ... , The study retrospectively screened 225 000 individual ... 2012 and Sept, 2013 for HEV RNA. 79 donors ...
(Date:7/27/2014)... Ticket Down is a reputable source for ... California on November 15th. This Australian boy band has recently ... songs from this amazing album at the concert. , Tickets ... The Forum will be released for sale to the general public ... TicketDown.com. This popular secondary ticket exchange can also be reached ...
(Date:7/27/2014)... According to a new market report ... Endoscopic Operative Devices, and Visualization Systems) - Global Industry ... global endoscopy devices market was valued at USD 24.9 ... a CAGR of 6.8% from 2013 to 2019, to ... 2019. , Endoscopy procedures are performed by inserting rod ...
(Date:7/27/2014)... Scientists from The University of Manchester have discovered why medication ... findings, published in Nature Medicine , show that drugs ... clock. , In the UK pneumonia, which is ... each year and is more serious for babies, young children, ... , More than 5 million people in the UK ...
Breaking Medicine News(10 mins):Health News:Baggy Eyes Serum Review Posted for Men and Women at Cherry News Website 2Health News:The Lancet: 1 in 3000 blood donors in England infected with hepatitis E 2Health News:5 Seconds of Summer Tickets at The Forum in Inglewood (Los Angeles), CA Now Available For Sale at Ticket Down 2Health News:Global Endoscopy Devices Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Global Endoscopy Devices Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Global Endoscopy Devices Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:Drugs used to treat lung disease work with the body clock 2
... Directors and Commits all ... Work to Benefit FASTeam, CHICAGO, July 7 Fetal ... Bifida, Down Syndrome and Muscular,Dystrophy combined, yet it is a ... prevention of prenatal alcohol exposure and,research examining the effects of ...
... play a major role in,keeping the bone marrow environment ... Tenn., July 7 The lack of a single,protein ... to,recycle molecules in cells causes an incurable and often ... Hospital investigators., Children with this disease, called sialidosis, ...
... chances of miscarriage for couple, study finds , , MONDAY, ... those in which the man is over age 35 have ... study shows. , To come to this conclusion, French researchers ... fertility clinic in France. , In most of the cases, ...
... San Francisco,s Largest AIDS Fundraising Event Goes GREEN with Online ... Communications, Recycling and Awareness, ... AIDS Walk San Francisco announced today key initiatives to ,Green, ... The,initiatives include the introduction of Green Walkers, composting, and,enhanced recycling., ...
... Athens Regional Medical Center and,Blue Cross and Blue ... multi-year contract, enabling Athens Regional to join the BCBSGa,HMO/POS ... PPO contract with,Athens Regional for many years., The ... throughout,Georgia will be able to gain complete access to ...
... Physicians Practice, America,s,Leading Practice Management Journal today ... to editorial director, Steven Gottshall to associate,publisher, ... promotions,are reflective of the company,s overall strategy ... into new physician focused markets and,circulation growth., ...
Cached Medicine News:Health News:K Squared Sponsors F.A.S.T. Ride 150-mile Motorcycle Tour August 17 2Health News:St. Jude Study Reveals a New Function for an Old Enzyme in Fatal Childhood Disease 2Health News:St. Jude Study Reveals a New Function for an Old Enzyme in Fatal Childhood Disease 3Health News:St. Jude Study Reveals a New Function for an Old Enzyme in Fatal Childhood Disease 4Health News:Father's Age a Factor in Infertility 2Health News:AIDS Walk San Francisco Takes Big Green Step Forward 2Health News:AIDS Walk San Francisco Takes Big Green Step Forward 3Health News:Blue Cross and Blue Shield of Georgia and Athens Regional Medical Center Announce New HMO/POS Contract 2Health News:Physicians Practice Promotes Key Executives 2
... safety and lower cost per test for the ... prep bottlenecks in the busy clinical lab... the ... quiet centrifuge spins standard 5 mL blood collection ... quality serum or plasma equal to 10-15 minute ...
... a unique closed system for performing fast, ... CenSlide 2000 system is microprocessor controlled to ... speed for one minute. At the end ... distributed evenly across the viewing area for ...
Used to provide drainage of urine from the bladder. All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open packages. Inte...
... internal drainage from the ureteropelvic ... sterile in peel-open packages. Intended ... evaluation is advised; polyurethane, C-Flex, ... remain indwelling more than six ...
Medicine Products: